One Of The Fusing Cells Is A Mouse Antibody-producing Cell Patents (Class 435/452)
  • Patent number: 9772331
    Abstract: The invention relates to a method and system for disease diagnosis that simultaneously detects antibodies bound to cellular and/or tissue substrates and antibodies bound to synthetic substrates, such as microparticles or beads coated with specific antigens, thereby providing a “one-step” method for the simultaneous detection and characterization of disease-associated antibodies at both low (cellular and/or tissue) and high (antigen) specificity.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: September 26, 2017
    Assignee: MEDIPAN GMBH
    Inventors: Ilka Knütter, Boris Radau, Dirk Roggenbuck
  • Publication number: 20150132322
    Abstract: This invention provides a human antibody, a hybridoma cell line for the production of the antibody, a reconstituted mouse strain for the production of the hybridoma, and methods of producing and using thereof.
    Type: Application
    Filed: May 6, 2013
    Publication date: May 14, 2015
    Inventors: Jean Elie Kadouche, Alain Razafindrastita
  • Patent number: 8900870
    Abstract: A method of forming a hybridoma cell includes acoustically focusing antibody producing cells in a first channel having a first acoustic field so as to produce a single file line of antibody producing cells; acoustically focusing immortal cells in a second channel having a second acoustic field so as to produce a single file line of immortal cells; flowing the acoustically focused single file lines of antibody producing cells and immortal cells to a third channel having a third acoustic field configured to bring at least one antibody cell and at least one immortal cell into close enough proximity to permit them to fuse; and fusing the antibody producing cell and the immortal cell together by at least one of a chemical and an electrical means to form at least one hybridoma cell.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: December 2, 2014
    Assignee: Life Technologies Corporation
    Inventors: Michael D. Ward, Gregory Kaduchak
  • Publication number: 20140199319
    Abstract: Disclosed herein are methods for improving the efficiency of the production of hybridomas, e.g., through enrichment of IgG expressing B cells. Also disclosed are hybridoma compositions produced using these methods as well as methods for producing antibodies with the hybridomas.
    Type: Application
    Filed: December 13, 2013
    Publication date: July 17, 2014
    Applicant: AbbVie, Inc.
    Inventors: Jane SEAGAL, Eve H. BARLOW, Chung-Ming HSIEH, Jeffrey Yen PAN, Shawn M. JENNINGS, Mary R. LEDDY, Archana B. THAKUR
  • Publication number: 20140201854
    Abstract: The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.
    Type: Application
    Filed: September 27, 2013
    Publication date: July 17, 2014
    Applicant: Kymab Limited
    Inventors: Allan Bradley, E-Chiang Lee, Qi Liang, Wei Wang, Anais Legent, Ian Kirby
  • Publication number: 20140073010
    Abstract: A method for engineering and utilizing large DNA vectors to target, via homologous recombination, and modify, in any desirable fashion, endogenous genes and chromosomal loci in eukaryotic cells. These large DNA targeting vectors for eukaryotic cells, termed LTVECs, are derived from fragments of cloned genomic DNA larger than those typically used by other approaches intended to perform homologous targeting in eukaryotic cells. Also provided is a rapid and convenient method of detecting eukaryotic cells in which the LTVEC has correctly targeted and modified the desired endogenous gene(s) or chromosomal locus (loci) as well as the use of these cells to generate organisms bearing the genetic modification.
    Type: Application
    Filed: November 14, 2013
    Publication date: March 13, 2014
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: ANDREW J. MURPHY, GEORGE D. YANCOPOULOS, MARGARET KAROW, LYNN MACDONALD, SEAN STEVENS
  • Patent number: 8642330
    Abstract: Antibody compositions and methods for inhibition of the effects of gonadotropin hormones are provided. Methods for treating cancer and methods for regulating fertility are provided by administration of the antibody compositions to a mammalian subject in need thereof.
    Type: Grant
    Filed: August 8, 2006
    Date of Patent: February 4, 2014
    Assignee: Onconon, LLC
    Inventors: Edwin P. Rock, Vernon C. Stevens, Pierre L. Triozzi
  • Publication number: 20130337467
    Abstract: The invention provides the sequences of two polypeptides comprising the amino acid sequences as shown in SEQ ID NO:1 and SEQ ID NO:2, which can be used for the preparation of monoclonal antibodies against human p28GANK. The invention also provides the monoclonal antibodies against human p28GANK and their use.
    Type: Application
    Filed: December 9, 2011
    Publication date: December 19, 2013
    Applicant: The Second Military Medical University, The People's Liberation Army
    Inventors: Hongyang Wang, Yao Chen, Jing Fu, Dongping Hu, Tao Luo, Liwei Dong
  • Patent number: 8501427
    Abstract: The invention relates to antibodies, including monoclonal and polyclonal, or fragments thereof, which discriminate between the histidine and tyrosine isoforms of Complement Factor H and to their use in diagnostic methods and therapeutic treatments relating to Complement Factor H mediated diseases.
    Type: Grant
    Filed: January 23, 2008
    Date of Patent: August 6, 2013
    Assignee: University College Cardiff Consultants Limited
    Inventors: Bryan Paul Morgan, Claire Louise Harris, Svellana Hakobyan
  • Patent number: 8415113
    Abstract: A procedure for the identification of a functional disorder of the pancreas by the use of parts of all iso-enzymes of the pancreas elastase and of synthetic amino-acid sequences as antigens for obtaining specific antibodies, as well as their use in immuno-chemical test procedures.
    Type: Grant
    Filed: September 3, 1999
    Date of Patent: April 9, 2013
    Assignee: R-Biopharm AG
    Inventors: Hans-Werner Heinrich, Rainer Kleinert, Udo Meyer, Heinz-Jürgen Wagner
  • Publication number: 20130059825
    Abstract: Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described. In addition, disclosed herein are methods for detecting vitamin D deficiency in a subject, methods for treating a subject suspected of having a vitamin D deficiency, methods for monitoring progression of vitamin D deficiency in a subject, and methods for monitoring treatment of vitamin D deficiency in a subject in need thereof. Also provided are methods and reagents for the detection or quantification of 25-hydroxyvitamin D2 and D3, methods for stabilizing vitamin D analogs, and methods for separating 25-hydroxyvitamin D2 and D3 from vitamin D binding protein in a biological sample.
    Type: Application
    Filed: April 27, 2012
    Publication date: March 7, 2013
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Niver Panosian Sahakian, Bruce A. Campbell, Spencer Hsiang-Hsi Lin, James Vincent Freeman, Qimu Liao, Ramon A. Evangelista
  • Publication number: 20120191163
    Abstract: A method of manipulating a living cell is disclosed. The method comprises, directing a pulsed optical field to at least one conductive nanoparticle present in the vicinity of the cell, so as to generate cavitations at or near the conductive nanoparticle at sufficient amount to effect at least one cell modification selected from the group consisting of cell-damage and cell-fusion.
    Type: Application
    Filed: January 19, 2012
    Publication date: July 26, 2012
    Applicant: Technion Research & Development Foundation Ltd.
    Inventors: Dvir Yelin, Limor Minai, Daniella Yeheskely-Hayon
  • Patent number: 8216842
    Abstract: The present invention provides methods of enhancing hybridoma fusion efficiencies through cell synchronization of the fusion partners, in order to aid in production of antibodies.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: July 10, 2012
    Assignee: Centocor Ortho Biotech Inc.
    Inventors: Jill Giles-Komar, Michael Rycyzyn, Gregory Bannish
  • Publication number: 20120088304
    Abstract: The present invention relates to cellular differentiation and, in particular to hybrid cells that exhibit phenotypic plasticity and methods for producing these cells. The invention also relates to methods for generating specific cells of a desired phenotype. The invention still further relates to methods of producing hybrid cells with a capacity to de-differentiate into an earlier progenitor state. The invention further contemplates the use of hybrid cells in a range of applications, for example tissue generation.
    Type: Application
    Filed: June 10, 2010
    Publication date: April 12, 2012
    Applicant: Stephen Sanig Research Institute Ltd.
    Inventors: Galina Kaseko, Tohsak L. Mahaworasilpa
  • Patent number: 8143025
    Abstract: Monoclonal antibodies that are specific for vascular endothelial growth factor receptor 1 (VEGFR-I). This invention also provides nucleotide sequences encoding and amino acid sequences comprising variable heavy and light chain immunoglobulin molecules, including sequences corresponding to the complementarity determining regions of CDR1, CDR2, and CDR3. The invention also provides methods for generation and expression of anti-VEGFR-I antibodies and methods of treating angiogenic-related disorders and reducing tumor growth by administering anti-VEGFR-I antibodies.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: March 27, 2012
    Assignee: ImClone LLC
    Inventors: Yan Wu, Peter Bohlen, Daniel J. Hicklin
  • Patent number: 7906297
    Abstract: The invention discloses two novel phosphorylation sites in human ATR kinase, serine 428 (Ser428) and serine 2317 (Ser2317) respectively, and provides reagents, including antibodies and AQUA peptides, that selectively bind to and/or detect ATR only when phosphorylated at one or more of these respective sites, but do not bind to ATR when not phosphorylated at these respective sites. Also provided are methods for determining the phosphorylation of ATR kinase in a biological sample, by using a detectable reagent that binds to ATR only when phosphorylated at Ser428 and/or Ser2317. Kits comprising the ATR (Ser428, Ser2317)-specific reagents of the invention are also provided.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: March 15, 2011
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Mark Livingstone, Hong Ruan, Robert Polakiewicz
  • Publication number: 20110052608
    Abstract: The present invention relates to a novel antibody which selectively binds to the disease associated form of prion protein (PrPSc) under native conditions and the use thereof in methods of prion disease detection, therapy and disease research in general.
    Type: Application
    Filed: June 13, 2007
    Publication date: March 3, 2011
    Applicant: UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH
    Inventors: Mark William Head, Michael Jones
  • Patent number: 7888485
    Abstract: The present invention concerns antibodies that neutralize at least one biological activity of pleiotrophin. The antibodies can inhibit cancer cell growth and angiogenesis in vitro or in vivo. The present invention provides for methods of inhibiting cancer cell growth or angiogenesis in a subject comprising administering to said subject an effective amount of the antibodies described herein. The present invention also provides for methods of making the neutralizing antibodies described herein.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: February 15, 2011
    Assignee: Georgetown University
    Inventors: J. Yun Tso, Anton Wellstein, Debra Chao
  • Patent number: 7842500
    Abstract: An antibody which reacts with N-acetylheparosan and heparan sulfate that is derived from bovine kidney but does not substantially react with heparan sulfate derived from a murine Engelbreath-Holm-Swarn tumor tissue, the antibody being produced with a hybridoma which is prepared using a substance composed of a protein and N-acetylheparosan bound to the protein.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: November 30, 2010
    Assignee: Seikagaku Corporation
    Inventors: Kiyoshi Suzuki, Takeshi Ishimaru, Koji Yamamoto
  • Patent number: 7829294
    Abstract: The present invention is directed to a monoclonal antibody against a soluble fibrin, which specifically recognizes a conformation-changed site newly occurred in a C-terminal region of an A?-chain of the soluble fibrin formed through thrombin digestion of fibrinogen. The present invention is also directed to a hybridoma which produces the antibody, an immunological assay method employing the antibody, and a method for evaluating hypercoagulability in a test sample by measuring the soluble fibrin level in the sample with the assay method. Through employment of the monoclonal antibody of the present invention, soluble fibrin on which plasmin has not acted, which reflects exclusively initial hypercoagulability, can be specifically detected.
    Type: Grant
    Filed: December 27, 2005
    Date of Patent: November 9, 2010
    Assignee: Daiichi Pure Chemicals Co., Ltd.
    Inventors: Masanao Matsuo, Hiroyuki Ebinuma, Osamu Miyazaki, Kyoko Tanaka, Akiko Suzuki
  • Patent number: 7811770
    Abstract: The present invention relates to antibodies specifically binding to native proBNP, a method for specific detection of native proBNP, a method of correlating the level of native proBNP to the diagnosis of heart failure, a kit for detection of native proBNP and to a hybridoma cell line producing an antibody to native proBNP.
    Type: Grant
    Filed: December 22, 2006
    Date of Patent: October 12, 2010
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Anneliese Borgya, Andreas Gallusser, Michael Grol, Klaus Hallermayer, Volker Klemt, Christoph Seidel
  • Patent number: 7807380
    Abstract: The present invention relates to antibodies specifically binding to native proBNP, a method for specific detection of native proBNP, a method of correlating the level of native proBNP to the diagnosis of heart failure, a kit for detection of native proBNP and to a hybridoma cell line producing an antibody to native proBNP.
    Type: Grant
    Filed: December 5, 2006
    Date of Patent: October 5, 2010
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Anneliese Borgya, Andreas Gallusser, Michael Grol, Klaus Hallermayer, Volker Klemt, Christoph Seidel
  • Publication number: 20100138936
    Abstract: The invention relates to the use of an expression vector construction coding for the functional HLA-DPal03?401 complex specifically identified by anti-HLA-DP antibodies, in order to create transgenic mice. The invention also relates to the use of the transgenic mice obtained, such as for the comparative preclinical study of the efficacy of vaccine candidates in order to asses the risks associated with the unwanted induction of an autoimmune disease and in order to determine a therapeutic strategy.
    Type: Application
    Filed: March 6, 2006
    Publication date: June 3, 2010
    Inventors: Yu-Chun Lone, Anthony Pajot, François Lemonnier
  • Patent number: 7728115
    Abstract: The invention includes compositions, kits and methods comprising a monoclonal antibody which shares key functional properties with the polyclonal antibodies which participate in the pathogenesis of heparin induced thrombocytopenia/thrombosis (HIT/HITT) in a mammal. The monoclonal antibody of the invention preferentially binds with a PF4/heparin complex relative to the binding of the antibody with PF4 or heparin alone. The monoclonal antibody of the invention also binds specifically with PF4 in a complex with other glycosaminoglycans besides heparin, and also activates platelets. The monoclonal antibody of the invention is useful in methods for diagnosing and treating HIT/HITT in a mammal. A humanized version of the monoclonal antibody of the invention is also included, along with a process for humanizing the monoclonal antibody of the invention.
    Type: Grant
    Filed: August 2, 2005
    Date of Patent: June 1, 2010
    Assignee: STC. UNM
    Inventors: Gowthami M. Arepally, Walter Kisiel, Keiko Kamei, Shintaro Kamei
  • Patent number: 7662928
    Abstract: Antibodies to heavy chain of human FcRn are provided which function as non-competitive inhibitors of IgG binding to FcRn. The antibodies may be polyclonal, monoclonal, chimeric or humanized, or antigen binding fragments thereof. These antibodies are useful for reducing the concentration of pathogenic IgGs in individuals and therefore used as a therapeutic tool in autoimmune and alloimmune conditions.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: February 16, 2010
    Assignee: The Research Foundation of State University of New York
    Inventors: Joseph P. Balthasar, Ryan J. Hansen, Feng Jin
  • Publication number: 20100028946
    Abstract: Fusion partner cells that enable production of heterohybridomas even from cells of species other than mouse were produced by fusing myeloma cells derived from a first animal species with leukemia cells derived from a second animal species, which have an extra S phase in the cell cycle and have the property of diploidizing. Stable production of substances can be achieved by producing heterohybridomas through cell fusion between the fusion partner cells and substance-producing cells of an animal other than mouse.
    Type: Application
    Filed: April 13, 2007
    Publication date: February 4, 2010
    Applicants: Medical & Biological Laboratories Co., Ltd.
    Inventors: Naomasa Yamamoto, Mizuho Kaneda
  • Patent number: 7611855
    Abstract: Using two types of antibodies, i.e., a first antibody having a higher affinity for a target substance than for a competitive substance and a second antibody having a higher affinity for the competitive substance than for the target substance, a specimen is treated with these two antibodies. Then, the competitive substance in the specimen first binds to the second antibody and thus the ratio of the target substance to the competitive substance in the specimen is enlarged. As a result, the target substance becomes liable to bind to the first antibody and, in its turn, the reactivity of the target substance is elevated compared with the case of using the first antibody alone. Thus, the target substance in the specimen can be accurately assayed while avoiding the effects of the competitive substance contained in the specimen.
    Type: Grant
    Filed: December 24, 2003
    Date of Patent: November 3, 2009
    Assignee: Nitto Boseki Co., Ltd.
    Inventors: Tatsuya Ohashi, Toshihide Miura, Yoshihiko Igarashi, Fumio Nomura, Takeshi Tomonaga, Katsuhiro Katayama
  • Patent number: 7541160
    Abstract: The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA method and kits for VEGF as an antigen were developed to detect VEGF levels in biological samples from animal models and human patients and are used as a diagnostic/prognostic index.
    Type: Grant
    Filed: November 1, 2004
    Date of Patent: June 2, 2009
    Inventors: David Tai Wai Fei, Kristen Tomita
  • Patent number: 7534580
    Abstract: In the serum, PSP94 occurs as a free form or is associated with a carrier protein. PSP94 in its bound form has been quantified in the blood of prostate cancer patients and these measurements have shown utility as evaluation or prognosis of prostate cancer. Diagnostic assays, methods, and kits for detecting a free form of PSP94, and reagents such as antibodies able to bind to a free form of PSP94 are disclosed herein.
    Type: Grant
    Filed: June 17, 2005
    Date of Patent: May 19, 2009
    Assignee: Ambrilia Biopharma Inc.
    Inventors: Jonathan Reeves, Edward Jerome Tanner, Chandra J. Panchal, Pierre Du Ruisseau
  • Patent number: 7527939
    Abstract: A specific and sensitive in vitro ELISA assay and diagnostic test kit is disclosed for determining levels of NT-proBNP protein in a variety of bodily fluids, non-limiting examples of which are blood, serum, plasma, urine and the like. The NT-proBNP ELISA assay test employs the sandwich ELISA technique to measure circulating NT-proBNP in human plasma. In order to obtain antibodies with specific binding properties for targeted amino acid sequences within human proBNP, recombinant human proBNP (or rhproBNP) was expressed and purified for use as an immunogen. Polyclonal antibodies (PAb) to specific amino acid sequences were subsequently purified from goat serum by sequential affinity purification. Monoclonal antibodies were raised against specific polypeptides. Recombinant human NT-proBNP (or rhNT-proBNP) was expressed and purified in order to obtain material for use in calibration of a quantitative method for measurement of human NT-proBNP.
    Type: Grant
    Filed: March 13, 2006
    Date of Patent: May 5, 2009
    Assignee: Nanogen, Inc.
    Inventors: Michelle Davey, George Jackowski, Peter Kupchak, Eric Stanton
  • Patent number: 7507550
    Abstract: The present invention concerns an immunological test for determining NT-proBNP comprising at least two antibodies to NT-proBNP, wherein at least one of the antibodies to NT-proBNP is a monoclonal antibody. One of these antibodies is directed at least against parts of the epitope of NT-proBNP comprising the amino acids 38 to 50. In addition, one of these antibodies is directed at least against parts of the epitope of NT-proBNP comprising the amino acids 1 to 37 or 43 to 76. The epitope recognized by the antibodies can slightly overlap.
    Type: Grant
    Filed: November 22, 2004
    Date of Patent: March 24, 2009
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Juergen Spinke, Alfons Nichtl, Volker Klemt, Klaus Hallermayer, Michael Grol, Anneliese Borgya, Andreas Gallusser
  • Patent number: 7504254
    Abstract: Novel bactericidal antibodies against Neisseria meningitidis serogroup B (“MenB”) are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The antibodies are used to identify molecular mimetics of unique epitopes found on MenB or E. coli K1. Examples of such peptide mimetics are described that elicit serum antibody capable of activating complement-mediated bacteriolysis of MenB. Vaccine compositions containing such mimetics can be used to prevent MenB or E. coli K1 disease without the risk of evoking autoantibody.
    Type: Grant
    Filed: October 5, 2005
    Date of Patent: March 17, 2009
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Dan M. Granoff, Gregory R. Moe
  • Patent number: 7473564
    Abstract: The invention concerns a kit for the detection of protein ESM-1 in a sample, comprising: a) a first antibody specifically binding to the N-terminal region of protein ESM-1 contained between the amino acid in position 20 and the amino acid in position 78 of the amino acid sequence of this protein; and b) a second antibody specifically binding to the C-terminal region contained between the amino acid in position 79 and the amino acid in position 184 of the amino acid sequence of protein ESM-1.
    Type: Grant
    Filed: November 8, 2001
    Date of Patent: January 6, 2009
    Assignees: Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale
    Inventors: Philipp Lassalle, David Bechard, André-Bernard Tonnel
  • Patent number: 7452977
    Abstract: The present invention relates, in general, to a kinase which in its activated state is capable of site-specific phosphorylation of I?B?, I?B? kinase. In particular, the present invention relates to the purified kinase, antibodies having binding affinity specifically to the kinase, and hybridomas containing the antibodies. This invention further relates to bioassays using protein or antibodies of this invention to diagnose, assess, or prognose a mammal afflicted with an undesired activation of NF-?B. This invention also relates to ligands, agonists, and antagonists of the kinase, and diagnostic and therapeutic uses thereof. This invention also relates to bioassays using the kinase to identify ligands, agonists, and antagonists. More specifically, this invention relates to selective inhibitors of the kinase.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: November 18, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Zhijian J. Chen
  • Patent number: 7264938
    Abstract: The present invention relates to antibodies specifically binding to native proBNP, a method for specific detection of native proBNP, a method of correlating the level of native proBNP to the diagnosis of heart failure, a kit for detection of native proBNP and to a hybridoma cell line producing an antibody to native proBNP.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: September 4, 2007
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Anneliese Borgya, Andreas Gallusser, Michael Grol, Klaus Hallermayer, Volker Klemt, Christoph Seidel
  • Patent number: 7264939
    Abstract: The present invention relates to antibodies specifically binding to native proBNP, a method for specific detection of native proBNP, a method of correlating the level of native proBNP to the diagnosis of heart failure, a kit for detection of native proBNP and to a hybridoma cell line producing an antibody to native proBNP.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: September 4, 2007
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Anneliese Borgya, Andreas Gallusser, Michael Grol, Klaus Hallermayer, Volker Klemt, Christoph Seidel
  • Patent number: 7244580
    Abstract: The present invention relates to identification of polypeptides useful for generating antibodies specific for non-human IgE, particularly equine IgE. The invention, therefore, also relates to antibodies that specifically bind to IgE and methods to detect IgE using the antibodies. The invention also provides a kit for detection of IgE.
    Type: Grant
    Filed: November 8, 2001
    Date of Patent: July 17, 2007
    Assignee: The Regents of the University of California
    Inventors: Laurel J. Gershwin, Howard David Pettigrew, Warren V. Kalina
  • Patent number: 7241578
    Abstract: The immunoassay method of this invention measures the content of a subject substance in a sample. The method includes the steps of: (a) preparing a mixed solution by mixing the sample and an antibody solution including a first monoclonal antibody and a second monoclonal antibody capable of specifically binding to the subject substance; and (b) measuring an optical property of the mixed solution. The first monoclonal antibody is capable of binding to a first epitope of the subject substance, and the second monoclonal antibody is capable of binding to a second epitope of the subject substance different from the first epitope. Each of the first and second epitopes exists singly in the subject substance.
    Type: Grant
    Filed: May 20, 2003
    Date of Patent: July 10, 2007
    Assignee: Matsushita Electric Industrial Co., Ltd.
    Inventors: Keiko Yugawa, Nobuyuki Shigetoh, Akihito Kamei, Tatsurou Kawamura
  • Patent number: 7138241
    Abstract: The present invention provides for a method of selecting an antibody against a target substance to be measured, which comprises selecting the antibody against the target substance by antigen-antibody reaction in the presence of a substance interfering with the antigen-antibody reaction. That is, an antigen and a labeled antigen are reacted with the antibody in the presence of an interfering substance, such as an environment pollutant, and on the basis of the degree of reaction thereof, the antibody against the target substance, which is highly resistant to the interfering substance, is selected. Thereby, even if a test sample is contaminated with a substance interfering with antigen-antibody reaction, the antibody, which is highly resistant to the substance interfering with antigen-antibody reaction, is not influenced by the interfering substance and gives a correct value in the quantification.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: November 21, 2006
    Assignee: Japan Envirochemicals, Ltd.
    Inventors: Yasuhiro Goda, Ayako Kobayashi, Masato Hirobe
  • Patent number: 7087727
    Abstract: The invention includes novel human periostin polypeptides and DNAs encoding them. Also embraced by the invention are human periostin specific antibodies, diagnostic assays for metastasis of breast cancer to bone, and preeclempsia.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: August 8, 2006
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Lan Bo Chen, Meiru Dai, Hidefumi Sasaki, Daniel Auclair
  • Patent number: 7087396
    Abstract: A method for determining a soluble human ST2 in a sample conveniently at a high sensitivity and an assay kit are provided. By an immunological method comprising a step for bringing a sample into contact with an immobilized antibody formed by binding to an insoluble support a first anti-human ST2 antibody which binds specifically to a non-denatured human ST2, a step for labelling a first reaction product generated in the previous step by reacting said first reaction product with a second anti-human ST2 antibody which binds specifically to a non-denatured human ST2 by recognizing a site different from the site on ST2 where said first anti-human ST2 antibody binds and which is labelled with a label, and a step for determining the amount of the label on said first reaction product which has been labelled, a soluble human ST2 in a sample is determined. In addition, a recombinant ST2 is employed as a standard to prepare a calibration curve, based on which the ST2 in a sample is quantified.
    Type: Grant
    Filed: September 16, 2002
    Date of Patent: August 8, 2006
    Assignees: Medical Biological Laboratories Co., Ltd.
    Inventors: Shin-ichi Tominaga, Takao Arai, Kenji Kuroiwa, Katsuhisa Oshikawa
  • Patent number: 7074903
    Abstract: Monocolonal antibodies having a higher reactivity with tartrate-resistant acid phosphatase 5b (TRACP 5b) than tartrate-resistant acid phosphatase 5a (TRACP 5a) and having a higher specificity to TRACP 5b can be obtained by cell fusion using as antigens TRACP 5b purified from human osteoclasts. By using the monoclonal antibody, TRACP 5b in a sample can be detected specifically with a high sensitivity.
    Type: Grant
    Filed: April 29, 2003
    Date of Patent: July 11, 2006
    Assignee: Nitto Boseki Co., Ltd.
    Inventors: Tatsuya Ohashi, Toshihide Miura, Yoshihiko Igarashi, Kumiko Sasagawa, Katsuhiro Katayama
  • Patent number: 6964854
    Abstract: The invention includes compositions, kits and methods comprising a monoclonal antibody which shares key functional properties with the polyclonal antibodies which participate in the pathogenesis of heparin induced thrombocytopenia/thrombosis (HIT/HITT) in a mammal. The monoclonal antibody of the invention preferentially binds with a PF4/heparin complex relative to the binding of the antibody with PF4 or heparin alone. The monoclonal antibody of the invention also binds specifically with PF4 in a complex with other glycosaminoglycans besides heparin, and also activates platelets. The monoclonal antibody of the invention is useful in methods for diagnosing and treating HIT/HITT in a mammal. A humanized version of the monoclonal antibody of the invention is also included, along with a process for humanizing the monoclonal antibody of the invention.
    Type: Grant
    Filed: July 13, 2000
    Date of Patent: November 15, 2005
    Assignee: Science & Technology Corporation
    Inventors: Gowthami M. Arepally, Walter Kisiel, Keiko Kamei, Shintaro Kamei
  • Patent number: 6951645
    Abstract: A “cocktail” combination of two monoclonal antibodies respectively acting on different sites of the platelet GPIIb-IIIa complex has been disclosed. This “cocktail” combination can completely block receptor function of the GPIIb-IIIa complex, inhibit platelet aggregation and thereby efficiently inhibit thrombosis.
    Type: Grant
    Filed: July 17, 2003
    Date of Patent: October 4, 2005
    Inventors: Changgeng Ruan, George Qingwei Ye
  • Patent number: 6949628
    Abstract: The invention relates to a process for in vitro diagnosis of an infection by human cytomegaloviruses. The process consists of contacting cells, possibly carrying the infection, with a monoclonal antibody reacting with a polypeptide of molecular weight 68,000, induced by human cytomegalovirus and which possesses a protein-kinase activity. The detection of the reaction is preferably carried out by immunofluorescence.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: September 27, 2005
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique, Institut National de la Sante de la Recherche Medicale
    Inventors: Florian Horaud, Susan Michelson, Octavian Barzu, Andre Boue, Claire Amadei
  • Patent number: 6927035
    Abstract: A monoclonal antibody which reacts strongly with uracil and thymine but scarcely with N-carbamyl-?-alanine; a hybridoma producing this monoclonal antibody; a method of immunochemically assaying uracil or thymine characterized by using the above-described monoclonal antibody; and diagnostics for DPD deficiency containing the above monoclonal antibody. Because of high sensitivity and specific reaction with uracil and thymine, the above-described monoclonal antibody enables convenient, quick, and selective assaying of uracil and thymine in a sample. The antibody is useful in screening patients with DPD deficient cancer with contraindication to the administration of pyrimidine fluoride-based antitumor agents.
    Type: Grant
    Filed: October 18, 2000
    Date of Patent: August 9, 2005
    Assignees: Taiho Pharmaceutical Co., LTD, Biomedical Research Group Inc.
    Inventor: Gen-ichiro Soma
  • Patent number: 6916628
    Abstract: The present invention provides a method for qualitative determination of low molecular weight soluble CD14 proteins separately. The present invention also provides antibodies specific to high molecular weight soluble CD14 proteins. Further, the present invention provides a measurement method for specifically determining the quality or quantity of high molecular weight soluble CD14 proteins using the antibodies with high sensitivity, simplicity and specificity.
    Type: Grant
    Filed: September 18, 2000
    Date of Patent: July 12, 2005
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Shouji Furusako, Kamon Shirakawa
  • Patent number: 6913894
    Abstract: Monoclonal antibodies which bind specifically to the extracellular domain of the SIRP cell surface glycoproteins, and which, in some cases, block the interaction of SIRP with the surface molecule CD47, are described.
    Type: Grant
    Filed: May 29, 2002
    Date of Patent: July 5, 2005
    Assignee: Eberhard-Karls-Universitat Tubingen Universitatsklinikum
    Inventors: Hans-Jörg Bühring, Axel Ullrich, Zhengjun Chen, Charles Cant
  • Patent number: 6893831
    Abstract: The present invention provides an immunoassay for specifically measuring with high sensitivity PIVKA-II in serum or plasma through antigen-antibody reaction by adding an animal serum containing thrombin and/or an antibody reacting with human fibrin-like related substances to the reagents. The immunoassay of the invention comprises the steps of adding thrombin and/or an antibody reacting with human fibrin-like related substances to the reagents, and measuring PIVKA-II in serum or plasma.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: May 17, 2005
    Assignee: Sanko Junyaku Co., Ltd.
    Inventors: Motohito Kanashima, Tomohide Asai, Hiroki Takahashi, Yoshiyuki Asai
  • Patent number: 6855508
    Abstract: The vascular endothelial growth factor (VEGF) activity in a patient's bloodstream or other biological sample can serve as a diagnostic and prognostic index for cancer, diabetes, heart conditions, and other pathologies. Antibody-sandwich ELISA method and kits for VEGF as an antigen were developed to detect VEGF levels in biological samples from animal models and human patients and are used as a diagnostic/prognostic index.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: February 15, 2005
    Assignee: Genentech, Inc.
    Inventors: David Tai Wai Fei, Kristen Tomita